Minirin (Desmopressin Acetate)

Desmopressin is a synthetic analogue of the natural hormone vasopressin. It selectively activates V2 receptors in the kidney’s collecting ducts, triggering a cascade that increases cyclic AMP and promotes insertion of aquaporin‑2 water channels into the cell surface. This enhances water reabsorption, concentrating urine, and also stimulates release of factor VIII from endothelial cells, aiding haemostasis.

The dose of Minirin is individualized by the prescribing clinician based on the patient’s age, weight, severity of the condition, and response to therapy. Typical regimens differ for central diabetes insipidus, nocturnal enuresis, and hemophilia A, and the prescriber may adjust the amount after monitoring clinical outcomes and laboratory values.

Safety data for desmopressin in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers usually assess the clinical need and may consider alternative therapies if safety cannot be assured.

To request Minirin, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue that offers a longer duration of action and greater selectivity for V2 receptors compared with natural vasopressin. This results in fewer cardiovascular side effects and the convenience of nasal administration. Other antidiuretics, such as thiazide diuretics, work through different mechanisms and may be less effective for central diabetes insipidus.

Minirin nasal spray should be stored at room temperature, below 25 °C (77 °F). Keep the container in its original packaging, protect it from moisture and direct sunlight, and avoid freezing. Do not refrigerate the product, as low temperatures can affect spray performance and stability.

The patient should gently blow the nose to clear the nasal passages, then tilt the head slightly forward. Insert the spray tip into one nostril, close the other nostril with a finger, and press the pump to deliver the prescribed number of sprays. Breathe in gently through the nose and avoid sniffing hard after administration.

The most serious risk is severe hyponatremia, which can lead to seizures, coma, or even death if fluid intake is not controlled. Additional serious concerns include thromboembolic events and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of low sodium and advised on appropriate fluid restriction.

Minirin should not be used in patients with existing hyponatremia, uncontrolled hypertension, or severe renal impairment. Individuals taking other antidiuretic agents, thiazide diuretics, or medications that predispose to low sodium should avoid concurrent use unless closely monitored. Pregnant or breastfeeding women should only use it when clearly indicated and after risk‑benefit assessment.